Create an account

Already have an account?
Technical support
The password is: uppercase and lowercase English letters and numbers, no less than 6 characters


Don’t have an account? Sign up
Forgot password?
AmoyDx Collaborates with Boehringer Ingelheim 
to Develop Companion Diagnostics for Lung Cancer Patients in China
Xiamen (China), May 22, 2024 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685) announced a collaboration with Boehringer Ingelheim for the development of a Companion Diagnostic (CDx) kit to identify those non-small cell lung cancer (NSCLC) patients who are most likely to benefit from targeted therapy.

In 2022 alone, 1,060,600 new cases of lung cancer were diagnosed making this group of cancers a leading cause of deaths in China*.

Boehringer Ingelheim is committed to transforming the lives of people living with lung cancer by delivering new and meaningful advances to the treatment landscape. To make this ambition a reality, Boehringer Ingelheim is cooperating with a growing global network of leading academic and industry partners to bring first-in-class innovation to patients with high medical need.

As a leading company in oncology companion diagnostics headquartered in China, AmoyDx is collaborating with cancer pharmaceutical companies to develop companion diagnostic programs aligned to their innovative drug development programs.

"We are aligned with Boehringer Ingelheim in our ambition to provide patients with the best cancer therapy and precision medicine solutions. AmoyDx has been focusing on tumor molecular diagnosis since its establishment in 2008. We are looking forward to collaborating with Boehringer Ingelheim to transform the lives of people with cancer through the implementation of precision medicine. said Li-Mou Zheng, Ph.D., Founder and Chairman of AmoyDx. 

About AmoyDx
Amoy Diagnostics Co., Ltd. is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe. For more information, please visit

Reference:  *Cancer incidence and mortality in China, 2022 - ScienceDirect

AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for TABRECTA (Capmatinib)


to our

Subscribe to our newsletter

Subscribe Now